Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AMBI Products LLC is a biotechnology company specializing in the manufacture and distribution of high-purity recombinant lysostaphin. Since 1991, the company has produced and marketed its flagship product, AMBICIN L, a highly purified preparation of recombinant lysostaphin used globally as an essential research and diagnostic tool for studying the molecular genetics and epidemiology of staphylococci. Recombinant lysostaphin is a potent bacteriolytic enzyme that specifically cleaves the pentaglycine cross-bridges in the cell wall of Staphylococcus aureus, making it highly effective for staphylococcal DNA preparation, protoplast transformation, and antimicrobial research. Headquartered in Lawrence, New York, AMBI Products serves academic, clinical, and industrial researchers worldwide.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on AMBI Products.